Marker Test Diagnostics, a leading international supplier to the drug testing industry, has secured its second agreement to distribute its UR Code urine marker product in the US with PSO Laboratory, a leading provider of drug confirmation testing and toxicology services in Michigan.
UR Code is a urine marker that "bar-codes" a subject’s urine and eliminates the need to supervise urine collection.
In the form of a soft gel capsule, UR Code is the only patented test worldwide that can analytically detect sample substitution, dilution or adulteration, resulting in unparalleled accuracy and reliability. This superior level of accuracy eliminates up to 30% of the tests that are deliberately falsified in urine drug testing.
The agreement provides PSO Labs with an exclusive and distinct competitive advantage to improve confirmation in all drug testing market segments in the state of Michigan and a non-exclusive in all other US markets. The companies plan to commercialize the product before the end of the summer.
"We are very proud to partner with PSO labs as an exclusive sole source distribution partner for the state of Michigan," said Marker Test Chief Executive Officer Kim Christensen.
"Marker Test’s unique patient identification system fits perfectly with PSO Laboratory’s focus on patient care, precision toxicology testing and patient responsibility," stated Michael Barna, M.D., Director of Laboratory Services for PSO Labs.
Representatives from Marker Test will be on-site during the 2015 American Association for Clinical Chemistry (AACC) Annual Meeting July 26-30 at the Georgia World Congress Center in Atlanta, Ga (booth 4918).
Founded in 2013, Marker Test Diagnostics is the producer of UR Code (TM), an innovative urine marker for the drug testing market.
Marker Test Diagnostics has completed research studies in the field of addiction and sports, and has collaborated and published scientific papers with the Olympic Doping Laboratory at the University of California Los Angeles, and the Columbia University / New York State Psychiatric Institute.